Pharmacokinetics and pharmacodynamics of dichloroacetate in patients with cirrhosis

Robert Shangraw, Dennis M. Fisher

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objectives: We tested the hypotheses that (1) plasma clearance of dichloroacetate is decreased in patients with end-stage cirrhosis, and (2) patients with cirrhosis are vulnerable to dichloroacetate-induced hypoglycemia caused by exaggerated inhibition of hepatic glucose production. Methods: Seven subjects with cirrhosis and six healthy volunteers received a 5-hour primed constant infusion of 6,6-2H2-glucose. After a 2-hour basal period, subjects received intravenous dichloroacetate, 35 mg/kg, over 30 minutes. Dichloroacetate pharmacokinetics were compared by the mixed-effects population-based technique. Glucose production was calculated by means of isotope dilution. Results: The optimal dichloroacetate pharmacokinetic model for both subjects with cirrhosis and control subjects had two compartments, with all parameters weight normalized. Peak plasma dichloroacetate concentration in subjects with cirrhosis did not differ from that in control subjects, but typical dichloroacetate clearance was only 36% of that in control subjects (P <.001). Dichloroacetate decreased plasma lactate concentration by ~50% (P <.001), glucose production by 7% to 9% (P <.05), and plasma glucose concentration by 9% to 14% (P <.05) in both subjects with cirrhosis and control subjects. Dichloroacetate-induced decreases in plasma lactate and glucose concentrations and in glucose production in subjects with cirrhosis did not differ from those in control subjects. Conclusions: Plasma dichloroacetate clearance is markedly decreased in patients with cirrhosis, likely because of compromised hepatic function. Subjects with cirrhosis exhibit neither exaggerated inhibition of glucose production nor increased risk of hypoglycemia as a result of acute dichloroacetate-induced hypolactatemia.

Original languageEnglish (US)
Pages (from-to)380-390
Number of pages11
JournalClinical Pharmacology and Therapeutics
Volume66
Issue number4
DOIs
StatePublished - 1999

Fingerprint

Fibrosis
Pharmacokinetics
Glucose
Hypoglycemia
Lactic Acid
Liver
Isotopes
Healthy Volunteers
Weights and Measures
Population

ASJC Scopus subject areas

  • Pharmacology

Cite this

Pharmacokinetics and pharmacodynamics of dichloroacetate in patients with cirrhosis. / Shangraw, Robert; Fisher, Dennis M.

In: Clinical Pharmacology and Therapeutics, Vol. 66, No. 4, 1999, p. 380-390.

Research output: Contribution to journalArticle

@article{6e030ccaf8e84a319239eb8112d49a88,
title = "Pharmacokinetics and pharmacodynamics of dichloroacetate in patients with cirrhosis",
abstract = "Objectives: We tested the hypotheses that (1) plasma clearance of dichloroacetate is decreased in patients with end-stage cirrhosis, and (2) patients with cirrhosis are vulnerable to dichloroacetate-induced hypoglycemia caused by exaggerated inhibition of hepatic glucose production. Methods: Seven subjects with cirrhosis and six healthy volunteers received a 5-hour primed constant infusion of 6,6-2H2-glucose. After a 2-hour basal period, subjects received intravenous dichloroacetate, 35 mg/kg, over 30 minutes. Dichloroacetate pharmacokinetics were compared by the mixed-effects population-based technique. Glucose production was calculated by means of isotope dilution. Results: The optimal dichloroacetate pharmacokinetic model for both subjects with cirrhosis and control subjects had two compartments, with all parameters weight normalized. Peak plasma dichloroacetate concentration in subjects with cirrhosis did not differ from that in control subjects, but typical dichloroacetate clearance was only 36{\%} of that in control subjects (P <.001). Dichloroacetate decreased plasma lactate concentration by ~50{\%} (P <.001), glucose production by 7{\%} to 9{\%} (P <.05), and plasma glucose concentration by 9{\%} to 14{\%} (P <.05) in both subjects with cirrhosis and control subjects. Dichloroacetate-induced decreases in plasma lactate and glucose concentrations and in glucose production in subjects with cirrhosis did not differ from those in control subjects. Conclusions: Plasma dichloroacetate clearance is markedly decreased in patients with cirrhosis, likely because of compromised hepatic function. Subjects with cirrhosis exhibit neither exaggerated inhibition of glucose production nor increased risk of hypoglycemia as a result of acute dichloroacetate-induced hypolactatemia.",
author = "Robert Shangraw and Fisher, {Dennis M.}",
year = "1999",
doi = "10.1053/cp.1999.v66.a101340",
language = "English (US)",
volume = "66",
pages = "380--390",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Pharmacokinetics and pharmacodynamics of dichloroacetate in patients with cirrhosis

AU - Shangraw, Robert

AU - Fisher, Dennis M.

PY - 1999

Y1 - 1999

N2 - Objectives: We tested the hypotheses that (1) plasma clearance of dichloroacetate is decreased in patients with end-stage cirrhosis, and (2) patients with cirrhosis are vulnerable to dichloroacetate-induced hypoglycemia caused by exaggerated inhibition of hepatic glucose production. Methods: Seven subjects with cirrhosis and six healthy volunteers received a 5-hour primed constant infusion of 6,6-2H2-glucose. After a 2-hour basal period, subjects received intravenous dichloroacetate, 35 mg/kg, over 30 minutes. Dichloroacetate pharmacokinetics were compared by the mixed-effects population-based technique. Glucose production was calculated by means of isotope dilution. Results: The optimal dichloroacetate pharmacokinetic model for both subjects with cirrhosis and control subjects had two compartments, with all parameters weight normalized. Peak plasma dichloroacetate concentration in subjects with cirrhosis did not differ from that in control subjects, but typical dichloroacetate clearance was only 36% of that in control subjects (P <.001). Dichloroacetate decreased plasma lactate concentration by ~50% (P <.001), glucose production by 7% to 9% (P <.05), and plasma glucose concentration by 9% to 14% (P <.05) in both subjects with cirrhosis and control subjects. Dichloroacetate-induced decreases in plasma lactate and glucose concentrations and in glucose production in subjects with cirrhosis did not differ from those in control subjects. Conclusions: Plasma dichloroacetate clearance is markedly decreased in patients with cirrhosis, likely because of compromised hepatic function. Subjects with cirrhosis exhibit neither exaggerated inhibition of glucose production nor increased risk of hypoglycemia as a result of acute dichloroacetate-induced hypolactatemia.

AB - Objectives: We tested the hypotheses that (1) plasma clearance of dichloroacetate is decreased in patients with end-stage cirrhosis, and (2) patients with cirrhosis are vulnerable to dichloroacetate-induced hypoglycemia caused by exaggerated inhibition of hepatic glucose production. Methods: Seven subjects with cirrhosis and six healthy volunteers received a 5-hour primed constant infusion of 6,6-2H2-glucose. After a 2-hour basal period, subjects received intravenous dichloroacetate, 35 mg/kg, over 30 minutes. Dichloroacetate pharmacokinetics were compared by the mixed-effects population-based technique. Glucose production was calculated by means of isotope dilution. Results: The optimal dichloroacetate pharmacokinetic model for both subjects with cirrhosis and control subjects had two compartments, with all parameters weight normalized. Peak plasma dichloroacetate concentration in subjects with cirrhosis did not differ from that in control subjects, but typical dichloroacetate clearance was only 36% of that in control subjects (P <.001). Dichloroacetate decreased plasma lactate concentration by ~50% (P <.001), glucose production by 7% to 9% (P <.05), and plasma glucose concentration by 9% to 14% (P <.05) in both subjects with cirrhosis and control subjects. Dichloroacetate-induced decreases in plasma lactate and glucose concentrations and in glucose production in subjects with cirrhosis did not differ from those in control subjects. Conclusions: Plasma dichloroacetate clearance is markedly decreased in patients with cirrhosis, likely because of compromised hepatic function. Subjects with cirrhosis exhibit neither exaggerated inhibition of glucose production nor increased risk of hypoglycemia as a result of acute dichloroacetate-induced hypolactatemia.

UR - http://www.scopus.com/inward/record.url?scp=0032742775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032742775&partnerID=8YFLogxK

U2 - 10.1053/cp.1999.v66.a101340

DO - 10.1053/cp.1999.v66.a101340

M3 - Article

C2 - 10546922

AN - SCOPUS:0032742775

VL - 66

SP - 380

EP - 390

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 4

ER -